An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance.
Significance: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib. Cancer Discov; 3(12); 1378–93. ©2013 AACR.
This article is highlighted in the In This Issue feature, p. 1317
The theory of dynamic, adaptive phenotype switching is based on the observation that unlike many other solid tumors, melanomas seem to downregulate signaling programs associated with proliferation to migrate (1, 2). These proliferative signaling programs are uniquely defined by genes involved in melanocyte differentiation and pigment production, such as MART1 and GP100, which are controlled by microphthalmia-associated transcription factor (MITF). MITF has been shown to be critical for the transformation of melanocytes and the growth and proliferation of primary melanomas. However, the expression of MITF and its downstream effectors MART1 and GP100 are often decreased in metastatic melanomas (2, 3). The role of MITF in phenotype switching has been the subject of much investigation. MITF can repress invasion via the regulation of Dia1 and subsequently p27/Kip1. Targeted loss of MITF increases both tumorigenesis (4) and metastatic potential, via increases in epithelial–mesenchymal transition (EMT) markers such as Snail, the reorganization of the actin cytoskeleton, and an increase in ROCK-dependent invasion (5). Hypoxia decreases the levels of MITF, as well as other melanocytic markers, driving the switch from a proliferative to an invasive phenotype (5, 6).
One of the other pathways intimately involved in the switch from a proliferative to an invasive phenotype in melanomas is the Wnt signaling pathway, which has also been shown to regulate the expression of MITF (7). Canonical Wnt signaling transduces signals that result in the stabilization of β-catenin, which is critical for the initial stages of melanoma development. In melanoma development, β-catenin stabilization is required to bypass melanocyte senescence (8), which results in melanocyte hyperproliferation, the activation of MITF, and, ultimately, transformation and tumor growth (7). However, the role of β-catenin in metastasis remains controversial. Forced β-catenin stabilization, in the very distinct genetic context of concomitant BRAF and PTEN mutations (9), promotes melanoma metastasis. This is supported by an additional study that shows that in an NRAS–driven model of murine melanoma, stabilization of β-catenin promotes metastasis (10). However, the same study shows that β-catenin can inhibit the migration of melanoma cells and of melanocytes via the induction of MITF, underscoring the complexity of the role of β-catenin in melanoma metastasis and invasion. In human melanoma cells, a recent study demonstrates that Wnt5A, when expressed in melanoma cells that express Frizzled 7, can activate β-catenin, also leading to an increase in invasion (11). Conversely, immunohistochemical analysis has demonstrated that nuclear β-catenin is a positive prognostic marker for melanomas (12). Further data also suggest that melanomas with active canonical Wnt signaling are less metastatic (and more proliferative) than those with active noncanonical Wnt signaling (12, 13), and at least two recent studies demonstrate that silencing β-catenin increases invasion and in vivo metastasis (14, 15). Recently, it has also been shown that BRAF-mutant melanomas that express elevated β-catenin are more sensitive to BRAF inhibitors (16). This suggests that β-catenin expression may predict not only a better prognosis in melanomas, but also a better response to targeted therapy. Overall, we speculate that the cohort of receptors, coreceptors, and Wnt ligands guide the fate of melanoma cells, and may predict their response to therapy (17).
The role of the noncanonical Wnt signaling molecule, Wnt5A, is more predictable than β-catenin, at least in melanomas. Multiple studies have shown that Wnt5A is increased in metastatic melanomas and can drive the invasion of melanoma cells (3, 11, 18–20). Overexpression of Wnt5A results in decreased proliferation and increased metastases in a B16 melanoma mouse model, as well as in human melanoma cells (3, 19, 21, 22). In addition to affecting metastasis, overexpression of Wnt5A downregulates the transcription of melanocytic antigens (MART1, GP100, and their promoters PAX3 and MITF) via the activation of STAT3 (3), resulting in a decrease in pigment, proliferation, and antigenicity of melanoma cells. All of these signaling changes downstream of Wnt5A promote the phenotype switch from early tumorigenesis to an advanced metastatic state. Furthermore, these effects require the expression of the tyrosine kinase receptor ROR2, and in the absence of ROR2, Wnt5A is unable to promote melanoma metastasis (21).
ROR2 is a tyrosine kinase receptor that specifically transduces Wnt5A signaling (23). Only one other member of this family has been identified thus far, ROR1 (24). ROR1 and ROR2 have an amino acid homology of 58% and are single-pass transmembrane proteins with immunoglobulin-like, cysteine-rich, and kringle domains on the extracellular portion (24). The intracellular domain contains both tyrosine and serine–threonine kinase domains (25). ROR1 has been shown to be an important molecule in the pathogenesis of cancers, such as acute lymphoblastic leukemia (26) and lung cancer (27), where it drives the survival and proliferation of these two cancer types. Like Wnt5A, ROR1 seems to play the opposite role in melanomas that it does in breast cancers. Wnt5A acts in a tumor-suppressive manner in breast cancers, but promotes the invasion and metastasis of melanoma cells. We show in this study that ROR1 inhibits the invasion of melanoma cells, but in breast cancer, ROR1 has been shown to promote an EMT and subsequent metastasis (28). Furthermore, ROR1 is associated with the increased growth of breast cancer cells (29). This discrepancy between breast cancers and melanomas has always been striking, but remains unexplained, and points again to the importance of cellular context in Wnt signaling.
Because ROR2 is critical for Wnt5A-mediated metastasis in melanomas (21), we sought to determine what role ROR1 might play in melanoma progression. Here, we show that despite its strong homology to ROR2, ROR1 is associated with the proliferative phenotype during early tumorigenesis of melanomas, rather than the invasive phenotype of metastatic disease, and therefore has opposing roles to ROR2 in melanoma progression. This is supported by recent data showing that ROR1 may play a role in the survival of melanoma cells (30). Intriguingly, we found that hypoxia guides the switch between the expression of the two highly homologous receptors, ROR1 and ROR2, providing a functional demonstration that hypoxia may act as one of the “triggers” for phenotype switching in melanoma crisis. We also demonstrate that this phenotypic switch may hold significant implications not only for tumor invasion, but also for therapy resistance.
ROR1 Marks a Poorly Invasive Phenotype in Melanoma Cells
Wnt5A and ROR2 levels are elevated in melanomas and are indicative of increased metastatic potential (21, 22). Phenotype switching in melanomas was first defined by Hoek and colleagues (2), who analyzed the gene expression profiles of several short-term cultures of melanoma cells. They found that their databases could be divided into cell lines that had low (cohort A) versus high (cohort C) invasive potential. Cells in cohort A (poorly invasive) were much more proliferative than those in cohort C. Markers of proliferation, such as MITF, were expressed in cohort A (proliferative) and Wnt5A was expressed in cohort C (invasive), and these markers clearly defined the proliferative from the invasive phenotype. We used this dataset largely because the invasive and proliferative phenotypes have been confirmed experimentally (2). We analyzed whether ROR1 gene expression was significantly decreased in this gene expression set, and found that ROR1 was more highly expressed in the proliferative cohort compared with the invasive cohort (Fig. 1A). In these samples, as opposed to Wnt5A expression (Supplementary Fig. S1A), the melanocytic markers MITF (Supplementary Fig. S1B), GP100 (Supplementary Fig. S1C), DCT (Supplementary Fig. S1D), and MART1 (Supplementary Fig. S1E) were also decreased in the more invasive cohort, suggesting that ROR1 is inversely associated with the invasive phenotype. We selected 10 melanoma cell lines that were either poorly invasive or highly invasive, and compared mRNA expression levels of ROR1(Fig. 1B) and ROR2 (Fig. 1C) using quantitative real-time PCR (qRT-PCR).Our results confirmed the microarray data, demonstrating an increase in ROR1 in poorly invasive samples, as compared with ROR2, which is elevated in highly invasive melanoma cells. We next compared ROR1 protein levels in six melanoma cell lines, in which we have previously established invasive capacity (3, 21, 22). ROR1 was not expressed in the three melanoma cell lines that are highly invasive (WM793, 1205LU, and M93-047), but the three that are poorly invasive (UACC1273, WM35, and WM1799) had robust ROR1 expression (Fig. 1D). We further confirmed this by using a three-dimensional (3D) skin reconstruct model, where artificial skin is built using keratinocytes, fibroblasts, and either melanocytes or melanoma cells of differing stages of progression (31). Serial sections were stained for ROR1, Wnt5A, and ROR2. ROR1 was expressed in melanocytes and in poorly invasive WM35 cells (Fig. 1E, melanocytes and WM35). ROR2 and Wnt5A, however, were expressed in more invasive WM793 cells (Fig. 1E, WM793) and in highly invasive 1205LU melanoma cells (Fig. 1E, 1205LU). These data are consistent with the gene expression data (Fig. 1A–C) that indicate that ROR1 is expressed in proliferative, poorly invasive cells, and its expression is decreased in metastatic cells.
Wnt5A Regulates ROR1 Expression
Because ROR1 is downregulated in metastatic melanomas and Wnt5A increases both ROR2 expression and melanoma metastasis, we asked whether Wnt5A could directly regulate levels of ROR1. Treatment with recombinant Wnt5A (rWnt5A) resulted in a significant downregulation of ROR1 mRNA in two poorly invasive cell lines (UACC1273 and G361) as measured by qRT-PCR (Fig. 2A). To confirm this at the protein level, we performed both Western blot analysis and surface biotinylation assays. Surface biotinylation assays determine the amount of ROR1 expression that is present at the cell surface and is available for ligand binding. ROR1 was decreased by rWnt5A treatment of Wnt5A-low UACC1273 cells, in contrast to ROR2, which was increased by rWnt5A treatment of these cells (21). In the high-Wnt5A, high-ROR2, metastatic cell lines UACC903, M93-047, and UACC647, we found no ROR1 expression (Fig. 2B). To determine how quickly ROR1 was degraded upon Wnt5A treatment, we treated Wnt5A-low G361 and UACC1273 cells with rWnt5A over a time course. ROR1 protein levels decreased significantly in as quickly as 5 minutes in both lines (Fig. 2C and Supplementary Fig. S2A). This suggested that the protein was being rapidly degraded upon Wnt5A treatment, and its decrease was not simply a result of decreased transcription.
To determine by which route ROR1 was degraded upon rWnt5A treatment, we analyzed the lysosomal and proteasomal degradation pathways. Immunofluorescent studies demonstrated that there is a fraction of ROR1 associated with lysosomes, even in the absence of rWnt5A (Supplementary Fig. S2A). However, the colocalization of ROR1 with lysosomes did not increase with rWnt5A treatment (Supplementary Fig. S2A). We next used the inhibitors Lys05 (32) and Bafilomycin 1 to inhibit lysosome function. Inhibition of lysosomal function with either of those inhibitors did not increase the accumulation of ROR1, suggesting that lysosomal degradation is not the primary mechanism for Wnt5A-mediated ROR1 degradation (Supplementary Fig. S2B). To determine whether ROR1 was being degraded via proteosomes, we treated ROR1-positive melanoma cells with the proteasome inhibitor MG132. In the presence of MG132, ROR1 accumulated in the cells (Fig. 2D and E, MG132). Treatment with rWnt5A decreased ROR1 expression (Fig. 2D and E, +rWnt5A), but in the presence of MG132 could no longer do so (Fig. 2D and E, MG132 + rWnt5A).
Many of the downstream events of Wnt5A are mediated via the activation of PKC, and the PKC isoforms activated by Wnt5A are protein kinase C (PKC) α, βII, and γ (22). To determine whether PKC activation plays a role in the Wnt5A-mediated downregulation of ROR1, we manipulated the activity of PKC in cells using the PKC inhibitor GO6983 (targeted to the conventional PKC isoforms). First, we treated Wnt5A-high UACC903 cells with GO6983. In control conditions, there was very little expression of ROR1, and Wnt5A was localized to endosomes, from where we have previously shown it is signaling (21). When PKC was inhibited (GO6983), Wnt5A was released from the endosomes and the levels of ROR1 were increased (Supplementary Fig. S3A). Western blot analysis showed that inhibition of PKC, even in Wnt5A-low cells, can also increase the levels of ROR1, suggesting that even the low levels of Wnt5A in these cells can regulate ROR1 (Fig. 2F). Next, we treated Wnt5A-low cells (G361, UACC1273) with rWnt5A in the presence or absence of PKC inhibitors, and asked how that affected ROR1 levels. In the absence of GO6983, cells have high levels of ROR1 (Fig. 2G and Supplementary Fig. S3B, UT). Treatment with rWnt5A decreased ROR1 expression (Fig. 2G and Supplementary Fig. S3B, +rWnt5A). In the presence of only the GO6983 inhibitor, ROR1 expression was unaffected (Fig. 2G and Supplementary Fig. S3B, +GO, 1 μmol/L). However, upon pretreatment of the cells with GO6983, rWnt5A was less efficient at decreasing ROR1, suggesting that PKC is required for the Wnt5A-mediated degradation of ROR1 (Fig. 2G and Supplementary Fig. S3B, GO + rWnt5A). Taken together, these data suggest that Wnt5A targets ROR1 to proteasomes for degradation in a PKC-dependent manner.
Loss of ROR1 Drives Melanoma Cell Invasion
Because ROR1 expression is decreased in metastatic melanoma cells, we sought to determine whether ROR1 knockdown could increase invasion. We used two different ROR1 siRNAs targeted to two different regions of the gene (ROR1_5 and ROR1_6). ROR1 knockdown resulted in an increase in both Wnt5A and ROR2 expression in multiple cell lines (Fig. 3A). To determine whether knockdown of ROR2 could similarly affect ROR1 expression, we knocked down ROR2 using a previously validated siRNA. ROR2 knockdown increased ROR1 expression (Fig. 3B and Supplementary Fig. S4A). To determine the effects of ROR1 knockdown on invasion, we subjected cells to 3D spheroid invasion assays, where cells were embedded in collagen. Knockdown of ROR1 significantly increased the invasion of poorly invasive WM35, WM983B, and WM1799 melanoma cells (Fig. 3C). Simultaneous knockdown of both ROR1 and ROR2 ablated invasion, suggesting that the primary way in which ROR1 mediates invasion is via the increase of ROR2 (Fig. 3C). These data suggest that ROR1 and ROR2 are reciprocally regulated and play opposing roles in melanoma invasion.
To translate these results in vivo, we knocked down ROR1 in WM35 and WM983B cells and injected those cells subcutaneously in nude mice. WM35 cells were allowed to grow for 60 days. For the first 20 days the knockdown of ROR1 significantly (***, P < 0.001) reduced the growth rate of these tumors. After that time, the growth rate increased to the level of the control, presumably due to the siRNA no longer being effective (Fig. 3D). WM983B cells, which grow faster than WM35 cells, were allowed to grow for 33 days. In these cells, ROR1 knockdown less significantly affected the growth rate of these tumors, but the trend was the same (Supplementary Fig. S4B). Animals bearing WM35 xenografted cells were euthanized and examined for metastases. Knockdown of ROR1 spurred the formation of visceral metastases by WM35 cells (Fig. 3E and F). In this cell line, knocking down ROR1 spurred the formation of metastases in the majority of animals (9 of 10). Interestingly, in animals xenografted with the control WM35 cells, previously thought to be radial growth phase (RGP) and not metastatic, we found evidence of one animal with a small number of metastases in the lungs.
Hypoxia Induces the Switch from ROR1 to ROR2, Increasing Invasion
Our data suggest that melanoma cells switch from an ROR1-positive to an ROR2-positive phenotype during melanoma invasion; we wanted to understand what initiated this switch. As melanoma cells invade more deeply into the skin, they encounter an increasingly hypoxic microenvironment, and the protein hypoxia-inducible factor-1α (HIF-1α) has been shown to be elevated as melanomas progress (33). HIF-1α plays a role in ROR2 upregulation (34) and is also inversely correlated with MITF expression in melanomas (5, 6, 35), so we analyzed the role of hypoxia in the induction of ROR1-to-ROR2 phenotype switching. First, we confirmed that exposure of melanoma cells to hypoxia (2% O2) increases their invasion using motility (scratch-wound) assays (Fig. 4A). HIF-1α expression was increased in the cells by 6 hours as expected (Fig. 4B). This upregulation was concomitant with a decrease in MITF and an increase in Wnt5A, suggesting that the phenotype switch occurs upon exposure to hypoxic conditions (Fig. 4C). To determine whether HIF-1α is responsible for Wnt5A upregulation following hypoxia, we knocked down HIF1A using siRNA (Fig. 4D). This resulted in the inability of hypoxia to induce Wnt5A expression (Fig. 4E), suggesting that HIF-1α is required for Wnt5A expression. These experiments were performed with two different siRNAs at 20 nmol/L (Supplementary Fig. S5A).
We next queried whether the ROR receptors are also affected by hypoxia. In the presence of hypoxia, ROR1 was downregulated (Fig. 4F and G), whereas ROR2 was upregulated (Fig. 4H). In the absence of HIF-1α, ROR2 was decreased (Fig. 4I). The hypoxia-mediated upregulation of ROR2 was blocked by Wnt5A silencing in highly invasive cell lines (Fig. 4J). In poorly invasive cell lines, there was little effect of Wnt5A silencing on ROR2 or HIF-1α during normoxic conditions, presumably because Wnt5A levels are already so low (Supplementary Fig. S5B). These data suggest that hypoxia is one factor that can drive the switch from a noninvasive ROR1-positive phenotype to an invasive, ROR2-positive phenotype. Furthermore, these data indicate that the upregulation of ROR2 via HIF-1α requires Wnt5A.
Wnt5A Upregulates Siah2, Stabilizing HIF-1α Levels, Resulting in Increases in ROR2
To understand how HIF-1α might work in cohort with Wnt5A to increase the expression of ROR2 during hypoxia, we looked for downstream signaling mediators in common between Wnt5A and HIF-1α. A common signaling intermediate in hypoxia and Wnt5A signaling is the E3 ubiquitin ligase, Siah2. Wnt5A regulation of canonical Wnt signaling occurs predominantly via upregulation of Siah2, resulting in a GSK3-β–independent degradation of β-catenin (36). Siah2 plays an important role during hypoxia, as it inhibits prolyl hydroxylases, resulting in the stabilization of HIF-1α (37). In addition, Siah2 is upregulated in metastatic melanomas (38), so we hypothesized that Siah2 upregulation may be downstream of Wnt5A in melanomas, just as it is during development.
We examined Siah2 expression in our melanoma cell lines. Siah2 expression was increased in Wnt5A-high UACC903 and M93-047 cells, as compared with Wnt5A-low UACC1273 cells (Fig. 5A), and knockdown of Wnt5A decreased Siah2 expression (Fig. 5B). This suggests that Wnt5A can indeed regulate Siah2 expression. To determine whether Siah2 is activated by hypoxia in melanoma cells, we exposed cells to hypoxia for 6 and 24 hours. Siah2 was increased in both poorly invasive (UACC1273) and highly invasive (M93-047) melanoma cells (Fig. 5C). To determine whether Wnt5A upregulation of Siah2 plays a role during hypoxia-initiated phenotype switching, we knocked down Wnt5A in invasive melanoma cells. When exposed to hypoxia, these cells were no longer able to upregulate Siah2 (Fig. 5D), and HIF-1α expression (Fig. 5E) was also decreased. This implies that Wnt5A is required for the activation of Siah2 during hypoxia and acts in a positive feedback loop with HIF-1α.
Because β-catenin is a target of Siah2, we sought to determine whether Wnt5A requires Siah2 to affect β-catenin levels in melanoma cells. We have previously shown that Wnt5A overexpression in proliferative phenotype melanoma cells can cause a decrease or dysregulation of β-catenin expression in those cells (39). Furthermore, CTNNB1 mRNA expression is downregulated in highly invasive compared with poorly invasive melanoma cell lines (2), and β-catenin expression can predict better patient outcome (13). rWnt5A treatment of Wnt5A-low UACC1273 cells resulted in a decrease of β-catenin expression, which, like ROR1, was dependent on proteasomal function (Fig. 5F). rWnt5A treatment of G361 cells also decreased β-catenin expression (Supplementary Fig. S5C). We then knocked down Siah2 in poorly invasive melanoma cells (Supplementary Fig. S5D), and showed that in the presence of Siah2 siRNA, β-catenin levels began to accumulate (Fig. 5G and Supplementary Fig. S5E). In the absence of Siah2, Wnt5A no longer affected β-catenin expression or localization (Fig. 5G and Supplementary Fig. S5E).
Taken together, these data demonstrate that hypoxia can drive the switch from ROR1 to ROR2 positivity in melanoma cells, and that Wnt5A, via Siah2, plays a critical role in the hypoxic induction of phenotype switching. These data provide evidence that microenvironmental regulation of noncanonical Wnt signaling is essential for the phenotypic plasticity of melanoma cells, and, further, these data identify HIF-1α as a novel target of noncanonical Wnt signaling. Our data also suggest that Siah2 may perform its function as a promoter of the metastatic phenotype of melanoma cells both via its stabilization of HIF-1α and its downregulation of β-catenin (see schematic in Fig. 5H).
Phenotype Switching in BRAF-Mutant Cells Decreases Sensitivity to BRAF Inhibitors
We then asked what the clinical implications of the observed phenotype switch might be. Previous studies have demonstrated that activated β-catenin expression sensitizes BRAF-mutant melanoma cells to vemurafenib therapy (16). We hypothesized that, conversely, Wnt5A-high melanoma cells with BRAF mutations might prove to be less sensitive to vemurafenib therapy. To analyze this, we identified cell lines with BRAFV600E mutations and measured their Wnt5A and ROR2 status, as well as their sensitivity to BRAF inhibitors. Out of 11 BRAF-mutant cell lines tested, with low and high Wnt5A, there was a significant correlation between BRAF inhibitor resistance and Wnt5A expression (P = 0.017; Fig. 6A). Treating PLX-sensitive 451LU melanoma cells with rWnt5A before the administration of the BRAF inhibitor PLX4720 increased the resistance of these cells to PLX4720 by almost 2-fold (Fig. 6B). ROR2 is the tyrosine kinase receptor responsible for Wnt5A signal transduction in melanomas, and the expression of this receptor was also increased in PLX-resistant cells (Fig. 6C).
To determine whether knockdown of ROR2 would sensitize Wnt5A-high cells to PLX4720, we treated resistant or partially resistant Wnt5A-high, ROR2-high cells (1205Lu, UACC62, and FS4) with siRNA directed against ROR2 (Supplementary Fig. S6A) and analyzed the cells for response to therapy. Knockdown of ROR2 sensitized melanoma cells to therapy in vitro (Fig. 6D and Supplementary Fig. S6B and S6C). To determine whether these results could be translated in vivo, we took partially resistant 1205LU melanoma cells and treated them with either control or ROR2 siRNA. These cells were then injected into nude mice subcutaneously. siRNA was delivered to the tumor site once a week by injection, a method we have previously shown to be effective in maintaining ROR2 gene silencing (21). ROR2 downregulation was maintained in these tumors as well (Supplementary Fig. S6D). Mice were divided into four groups: (i) control siRNA + PLX4720-laced chow (AIN-76A, with 417 mg/kg PLX4720), (ii) control siRNA + untreated chow (AIN-76A), (iii) ROR2 siRNA + PLX4720-laced chow (AIN-76A, with 417 mg/kg PLX4720), and (iv) ROR2 siRNA + untreated chow (AIN-76A). Pretreatment of PLX-resistant 1205Lu cells with ROR2 siRNA dramatically increased the response to PLX4720 in vivo compared with control siRNA (Fig. 6E). In contrast, knockdown of ROR2 did not significantly affect the proliferation of tumor cells in the absence of PLX4720 (Fig. 6E).
Next, we asked whether ROR1 was decreased in resistant cells and whether the knockdown of ROR1 could affect the response to PLX4720. ROR1 expression was decreased in PLX4720-resistant cells (Fig. 6F). We performed a similar experiment using WM35 and WM983B melanoma cells, which both express ROR1 and are sensitive to PLX. Animals bearing xenografted tumors, either control siRNA or ROR1 siRNA treated, were fed chow containing PLX4720 after tumor development. Tumors were measured for a period of 3 weeks. The results showed that the knockdown of ROR1 significantly (*, P < 0.01) decreased sensitivity to PLX4720 both in WM35 cells (Fig. 6G) and in WM983B cells (Supplementary Fig. S6E; P < 0.004). These data imply that inhibition of ROR2 in conjunction with BRAF inhibitors may target a subset of patients not previously responsive to these drugs. Also, the loss of ROR1 increases the resistance to PLX4720, further confirming the observation that the microenvironment can guide a phenotype switch to a more aggressive tumor type.
Wnt5A Expression Correlates with Resistance in Human Tumor Samples
To further confirm and extend these findings, we sought to assess whether the expression of Wnt5A could predict patient response to vemurafenib in a small cohort of patients (n = 24). Robust clinical response to vemurafenib is defined as 30% response or higher. To account for human error in measuring response, we extended this definition of clinical response to include samples of 35% or higher. We were able to identify 9 patients with 33% response or lower to vemurafenib and 15 patients with a 38% or higher response to the drug. Examples of Wnt5A staining in correlation with therapeutic response are shown in Fig. 7A. Treatment, time to progression, and survival were assessed in this cohort of patients, and the data are summarized in Supplementary Table S1. Even in this small cohort of patients, the results were significant: 7 of 9 patients who demonstrated less than 33% clinical response to vemurafenib had positive expression of Wnt5A, from 1–3+ intensity. Only 2 of the remaining 15 patients (38% response or greater) exhibited any Wnt5A expression (1–2+ intensity), as shown in Fig. 7B, giving a statistical significance of P = 0.002. It should be noted that although ROR1 and ROR2 status would also likely provide further evidence of resistance to therapy, the antibodies available are not robust enough for reliable formalin-fixed, paraffin-embedded (FFPE) analysis.
If Wnt5A truly confers clinical resistance to BRAF inhibitors, then we would predict that Wnt5A-positive cells might be selected for in patients who relapse (become resistant) while on therapy. To test this, we acquired 12 patient samples that had undergone BRAF inhibitor therapy and for whom we had pre- and posttherapy, relapsed lesions. We scored the levels of Wnt5A expression in these samples and found that 8 of 12 postrelapse samples had increased Wnt5A positivity compared with pretherapy lesions (i.e., positivity in a larger percentage of the tumor). Two examples are shown in Fig. 7C. In these 8 patients, positivity increased from an average of 6% of the tumor cells being positive for Wnt5A pretherapy, to an average of 52% of the tumor cells being positive postrelapse (P = 0.016). In the remaining 4 patients, one sample increased from 25% to 30% positivity (which we did not consider significant and therefore scored as unchanged), one remained the same (5% positivity, pre-, and post-), one decreased from 16% positivity to 10% positivity, and one decreased from 5% positivity to no positivity. All the data are summarized in Supplementary Table S2. When considering all 12 tumors together, the overall increase in Wnt5A staining went from 8% positivity pretherapy to 38% positivity postrelapse, and was significant at P = 0.018. Interestingly, in one sample for which we had pretreatment, on-treatment, and postrelapse samples, Wnt5A staining increased from 0% to 80% positivity in the on-treatment sample, to 100% positivity (and an increase from 1–2+ intensity) in the postrelapse sample.
We also examined resistant cells in vitro. We took resistant subclones of the PLX-sensitive cell line WM983B (40), which are initially sensitive to BRAF inhibitors. This acquired resistance can be demonstrated by the failure of PLX4720 to inhibit extracellular signal–regulated kinase (ERK) activation in the resistant cells compared with the parental cells (Fig. 7D). Next, we analyzed the resistant subclones for their ROR1, ROR2, and Wnt5A status. Compared with the parental cell lines, resistant subclones lost ROR1 expression and increased their levels of Wnt5A and ROR2 (Fig. 7E). We asked whether treatment of sensitive cells with Wnt5A could increase ERK activation, and, indeed, 451LU and WM983B cells treated with Wnt5A had increased phosphorylated–ERK expression (Fig. 7F), suggesting that activation of Wnt5A may provide an alternate route to maintaining mitogen-activated protein kinase (MAPK) signaling in the face of BRAF inhibition. These data suggest that the Wnt5A pathway plays a role in resistance to BRAF inhibitors and may represent both a viable target for adjuvant therapy in patients with melanoma harboring the BRAF mutation, as well as a valuable prognostic indicator of therapy response. These data highlight the fact that the mechanisms that underlie the phenotypic plasticity leading to increased invasion and those that underlie therapy resistance are very tightly connected.
Understanding the mechanisms that underlie phenotype switching and the role it plays in the generation of aggressive, therapy-resistant melanoma cells is of increasing importance in melanoma biology. We have long postulated that melanoma cells make decisions whether to “grow or go.” Although this has obvious implications for metastasis, we are just beginning to appreciate the extent to which metastatic signaling programs may also guide therapy resistance. Changes in molecules such as MITF and Wnt5A guide a switch to a mesenchymal, invasive population of melanoma cells. In this study, we show that the mechanisms by which Wnt5A guides one outcome (metastasis) may have a significant impact on another (therapy resistance).
The Wnt signaling pathway consists of several Wnts that signal via β-catenin (canonical Wnt signaling) and others that signal via PKC, Ca2+, and Jnk (noncanonical Wnt signaling). The dynamic between the different members of this family of proteins is of increasing interest in melanoma biology. Wnt5A, a noncanonical Wnt, does not seem to play a role in melanocyte transformation, yet is critical for driving melanoma metastasis. The role of β-catenin in melanocyte transformation and melanoma growth is abundantly clear; its role in metastasis is less so, with most studies indicating that β-catenin signaling decreases during progression (7, 8, 41, 42). Furthermore, the suppression of β-catenin has been shown to increase invasion in melanoma cells (43). In contrast, a recent study indicates that stabilizing β-catenin in the context of both a BRAF mutation and a PTEN deletion increases metastatic progression (9), but it is unclear how often this defined genetic profile (BRAFV600E/PTEN−/−/CTNNB1STA) occurs in patients with melanoma. Overall, most data imply that during melanoma invasion, melanoma cells switch from a canonical Wnt signaling pathway to a noncanonical Wnt signaling one.
Although Wnt ligands can be quite promiscuous, the coreceptor, ROR2, is faithful in activating the noncanonical Wnt signaling pathway. Here, we describe for the first time the regulation and loss of a tyrosine kinase receptor not previously associated with melanoma, the ROR1 receptor. In other cancers, ROR1 plays a protumorigenic role, driving the growth, survival, and tumorigenic transformation of MET-driven cancers, including gastric, renal, and non–small cell lung cancers (27, 44–47). Taken together, these data point to a role for ROR1 in driving tumor growth. However, the role of ROR1 in melanomas has not been previously assessed. We show that knockdown of ROR1 decreases melanoma cell proliferation in vivo, implicating it in growth. We show that Wnt5A can signal to increase the proteasomal degradation of ROR1, such that ROR1 is decreased during invasion. When ROR1 expression is decreased, that of Wnt5A and ROR2 increases, and this corresponds to increases in invasion and metastasis. These data indicate that although ROR1 may play a role in melanoma cell growth, its loss is necessary for invasion, underscoring the increasingly common observation that factors driving tumor growth may be quite distinct from those that drive tumor metastasis.
Hypoxia has been shown to be a driving force for the metastatic progression of melanomas (38, 48). In addition, ROR2 is postulated to be a target of HIF-1α (34). We hypothesized that as tumors become larger and increase their hypoxic regions, the activation of ROR2 could drive increased aggression, increased Wnt5A signaling, and decreases in ROR1. Indeed, our data show that in the presence of hypoxia, ROR1 expression decreases, and expression of ROR2 and Wnt5A increases, in a HIF-1α–dependent manner. Surprisingly, we found that Wnt5A plays a critical role in the stabilization of HIF-1α via the E3 ubiquitin ligase Siah2. Siah2 is activated during hypoxia via phosphorylation of its serine/threonine residues, and acts to stabilize HIF-1α. Research has shown that Wnt5A can act via ROR2 to increase Siah2 phosphorylation and activity (49), and we confirmed that finding in this study. However, we also show for the first time that through this activation of Siah2, Wnt5A is also able to stabilize HIF-1α, highlighting HIF-1α as a novel downstream target of Wnt5A.
In addition to increasing invasion, hypoxic upregulation of Wnt5A/ROR2 has another important corollary. By upregulating Siah2, Wnt5A is able to downregulate β-catenin. β-Catenin expression has been shown to sensitize melanoma cells to BRAF inhibitors (16), leading us to postulate that if Wnt5A signaling decreased β-catenin, then Wnt5A should make melanoma cells more resistant to BRAF inhibitor therapy. Indeed, our data indicate that Wnt5A plays a role in intrinsic resistance, as patients with melanoma tend to respond poorly to vemurafenib if they express higher levels of Wnt5A. Although this is a small sample size, Wnt5A expression in pretreatment biopsies accurately predicted response to BRAF inhibitors in 7 of 9 nonresponder (less than 35% response) patient samples, and in 13 of 15 responders. Furthermore, analysis of patient tumors pre- and post-BRAF inhibitor therapy demonstrates significant increases in Wnt5A expression. This may be attributable to the fact that Wnt5A-positive cells are more intrinsically resistant to BRAF inhibitors; therefore, it is this resistant subpopulation that continues to survive during BRAF inhibitor therapy, and ultimately dominates. Alternatively, inhibition of BRAF in Wnt5A-high cells may drive increased MAPK signaling via the Wnt5A pathway.
The link between the mechanisms that underlie tumor metastasis and therapy resistance is not well defined; however, it is clear that tumors that are more aggressive are likely to be more resistant to therapy. Yet, predicting which tumor is likely to metastasize faster when comparing stage IV tumors is challenging. Thus, the use of Wnt5A as a prognostic marker for both time of progression-free survival as well as therapy response may be of great clinical utility. Other data from our laboratory further implicate Wnt5A in resistance to other forms of therapy, and this is mediated by Wnt5A control of β-catenin (Webster and colleagues, submitted for publication). This is supported by a recent study that implicates β-catenin in resistance not only to BRAF inhibitors, but also to MEK inhibitors (50). It should be noted that increases in Wnt5A expression posttherapy were observed in patients with melanoma who received both BRAF inhibitors and ERK inhibitors (Supplementary Table S2). Thus, targeting the Wnt5A/ROR2 pathway may not only increase initial sensitivity to BRAF inhibition as demonstrated in our animal studies, but may also provide a useful mechanism for targeting relapsing tumors. Ongoing work in our laboratory seeks to identify small-molecule inhibitors of ROR2, hoping that we can use them to generate more effective and durable responses to vemurafenib. Importantly, as the ROR2 pathway also drives melanoma metastasis, such inhibitors could be of great clinical benefit in the 50% of patients who do not carry the BRAFV600E mutation.
Extended Methods are available as Supplementary Data.
UACC1273EV, UACC903, M93-047, and UACC647 cells were maintained in RPMI (Invitrogen). G-361 cells were maintained in McCoy's 5A media (Invitrogen). All the above cell line media were supplemented with 10% FBS, 100 U/mL penicillin and streptomycin, and 4 mmol/L l-glutamine. 451LU and WM983B cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 5% FBS. 451LU BR (BRAF inhibitor resistant) and WM983B BR cells were maintained in DMEM with 5% FBS containing 1 μmol/L/mL PLX4720. Melanocytes were maintained in Medium 254CF containing Human Melanocyte Growth Supplement-2 without phorbol 12 myristate 13 acetate (PMA; HMGS-2; Invitrogen). WM35, WM793, 451LU, and 1205LU cells were maintained in MCDB153 (Sigma)/L-15 (Cellgro; 4:1 ratio) supplemented with 2% FBS and 1.6 mmol/L CaCl2. Fibroblasts were maintained in DMEM and supplemented with 10% FBS. Keratinocytes were maintained in keratinocyte serum-free media supplemented with human recombinant EGF 1-53 and bovine pituitary extract (BPE; Invitrogen). Cell lines were cultured at 37°C in 5% CO2 and the medium was replaced as required. Cell stocks were fingerprinted using AmpFLSTR Identifiler PCR Amplification Kit from Life Technologies at The Wistar Institute Genomics Facility. Although it is desirable to compare the profile with the tissue or patient of origin, our cell lines were established over the course of 40 years, long before acquisition of normal control DNA was routinely performed. However, each short-tandem repeat (STR) profile is compared with our internal database of over 200 melanoma cell lines as well as control lines such as HeLa and 293T. STR profiles are available upon request. Cell culture supernatants were Mycoplasma tested using a Lonza MycoAlert assay at the University of Pennsylvania Cell Center Services.
For rWnt5A treatment, concentrations and treatment times were as previously established to be optimal for these cells (19). For inhibition of lysosomes and 26S proteasomes and hypoxic treatment doses and times, see Extended Methods.
HP-validated CTRL, Wnt5A, HIF1A (2), Siah2 (2), ROR1 (2), and ROR2 siRNAs (20–200 nmol; Qiagen) were transfected into cells using Lipofectamine (Invitrogen) as previously described (21). siRNA sequences are listed in Supplementary Table S1.
Organotypic 3D Skin Reconstructs
Organotypic 3D skin reconstructs were generated as previously described (51). Melanocytes and melanoma cell lines at different stages of progression [RGP, vertical growth phase (VGP), and metastatic] were used to generate the reconstructs. Please refer to the Supplementary Data for details.
Cellular Proliferation and Motility Assays
MTS assays were used to determine cell proliferation. Motility assays were performed as previously described (21). Please refer to the Supplementary Data for details.
3D Spheroid Assays
The formation of spheroids is outlined in the Supplementary Data. Collagen plugs were fixed in 1:10 formalin for 10 minutes, processed into paraffin blocks, and sectioned onto slides.
The primary antibodies used were: Wnt5A (10 μg/mL; R&D Systems), ROR1 (2.5 μg/mL), ROR2 (2.5 μg/mL), HIF-1α (0.5 μg/mL), phospho–β-catenin (T41/S45; 1 μg/mL), β-catenin (0.5 μg/mL; Cell Signaling Technology), MART1 (2 μg/mL; Thermo Scientific), and LAMP2 (5 μg/mL; Abcam). For details please refer to the Supplementary Data.
Patient samples were collected under Institutional Review Board (IRB) exemption approval for protocol #EX21205258-1. Samples were stained for Wnt5A expression using a biotinylated Wnt5A antibody (R&D Systems). For details please refer to the Supplementary Data.
Mouse ROR2 siRNA PLX4720 Assay
All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC; IACUC #112503X_0) and were performed in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)–accredited facility. 1205LU cells were transfected with CTRL or ROR2 siRNA as described above. Forty-eight hours following transfection, 7.5 × 105 cells suspended in PBS/Matrigel (500 μg/mL) were subcutaneously injected into each 6-week-old female athymic nude mouse (Charles River Laboratories). Mice were injected intratumorally with 150 nmol/L siRNA once a week until euthanized. When resulting tumors reached 200 mm3, mice were fed either AIN-76A chow or AIN-76A chow containing 417 mg/kg PLX4720. Tumor sizes were measured every 3 to 4 days using digital calipers, and tumor volumes were calculated using the following formula: volume = 0.5 × (length × width2). Time-to-event (survival) was determined by a 5-fold increase in baseline volume (∼1,000 mm3) and was limited by the development of skin necrosis. Upon the occurrence of necrosis, mice were euthanized. Tumors were harvested, paraffin embedded, and sectioned.
Mouse ROR1 siRNA PLX4720 Assay
WM35 and WM983B cells were transfected with CTRL or ROR1 siRNA (two different siRNAs) as described above. Forty-eight hours following transfection, 1 × 106 cells suspended in PBS/Matrigel (500 μg/mL) were subcutaneously injected into each 6-week-old female athymic nude mouse (Charles River Laboratories). Mice were injected intratumorally with 100 nmol/L siRNA once a week until euthanized. After 33 days of growth, mice injected with WM35 cells were fed either AIN-76A chow or AIN-76A chow containing 417 mg/kg PLX4720. Mice injected with WM983B cells were fed AIN-76A chow containing 417 mg/kg PLX4720. Tumor sizes were measured every 3 to 5 days using digital calipers, and tumor volumes were calculated using the following formula: volume = 0.5 × (length × width2). Time-to-event (survival) was determined by a 5-fold increase in baseline volume (∼1,000 mm3) and was limited by the development of skin necrosis. Upon the occurrence of necrosis, mice were euthanized. For all mice, tumors were harvested, and for WM35 mice the lungs were also analyzed for metastasis.
For in vitro studies, Student t test or ANOVA was performed using at least three independent experiments. For in vivo studies, the fold change in tumor volume after treatment at 14 days relative to baseline was used to evaluate the treatment effect. Means, SDs, and medians were calculated and distributions of data were examined to ascertain whether normal theory methods are appropriate. The Kruskal–Wallis test and post hoc Wilcoxon rank-sum test were used for multiple comparisons among experimental groups. Bonferroni's adjusted P values were calculated and used to determine the statistical significance. For patient samples, paired t tests were used to calculate significance. Stata 12.0 (StatCorp LP) was used for data analysis. Significance was designated as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Disclosure of Potential Conflicts of Interest
M. Herlyn has received commercial research grants from Novartis, GlaxoSmithKline, and Boeringer-Ingelheim. K.T. Flaherty is a consultant/advisory board member of GlaxoSmithKline and Roche/Genentech. J.A. Wargo has received honoraria from the Speakers Bureau of DAVA Oncology. No potential conflicts of interest were disclosed by the other authors.
Conception and design: M.P. O'Connell, K. Marchbank, M.R. Webster, M. Herlyn, K.T. Flaherty, A.T. Weeraratna
Development of methodology: M.P. O'Connell, K. Marchbank, M.R. Webster, A.A. Valiga, A. Vultur, L. Li, N. Ruiz, T.C. Camilli, F.E. Indig, K.T. Flaherty, A.T. Weeraratna
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.P. O'Connell, K. Marchbank, M.R. Webster, A.A. Valiga, A. Kaur, A. Vultur, L. Li, J. Villanueva, S. Widura, N. Ruiz, F.E. Indig, K.T. Flaherty, J.A. Wargo, D.T. Frederick, Z.A. Cooper, S. Nair, R.K. Amaravadi, L.M. Schuchter, G.C. Karakousis, W. Xu, X. Xu, A.T. Weeraratna
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.P. O'Connell, K. Marchbank, M.R. Webster, A.A. Valiga, A. Kaur, A. Vultur, M. Herlyn, Q. Liu, X. Yin, J. Nelson, F.E. Indig, K.T. Flaherty, J.A. Wargo, R.K. Amaravadi, X. Xu, A.T. Weeraratna
Writing, review, and/or revision of the manuscript: M.P. O'Connell, K. Marchbank, M.R. Webster, A. Vultur, M. Herlyn, K.T. Flaherty, J.A. Wargo, R.K. Amaravadi, L.M. Schuchter, G.C. Karakousis, X. Xu, A.T. Weeraratna
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.P. O'Connell, W. Xu, X. Xu, A.T. Weeraratna
Study supervision: M.P. O'Connell, A.T. Weeraratna
Consent patients, human subject specimens, and data collection: W. Xu
This work was supported in part by funds from the National Institute on Aging Intramural Research Program (to F.E. Indig and T.C. Camilli), PA Department of Health (CURE) funding (to A.T. Weeraratna, M.P. O'Connell, K. Marchbank, A. Vultur, N. Ruiz, Q. Liu, X. Yin, and S. Widura), and the Joanna M Nicolay Foundation (to A. Kaur). Additional support for other authors comes from PHS 2 T32 CA 9171-36 (to M.R. Webster), 1K23CA120862 (to R.K. Amaravadi), and CA25874 (to M. Herlyn).
The authors thank Dr. Gideon Bollag for access to the PLX4720- laced AIN-76A chow and Dr. Dario Altieri for critical reading of the article and helpful comments. The authors also thank the Histology and the Imaging Core Facilities of The Wistar Institute (Philadelphia, PA).
Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).
- Received January 3, 2013.
- Revision received October 2, 2013.
- Accepted October 4, 2013.
- ©2013 American Association for Cancer Research.